Search Results

64/2022-the Subject Of The Order Is The Successive Delivery Of Oncological Drugs, Drugs For The Treatment Of Ms, Infusion Fluids, Antibiotics, Albumins, Desflurane, Sevoflurane, Contrast Agents, Heparins.

• Source: Mena Report. 2024.

Record details

Scientists in yeast move raise hopes over cancer drugs.

• Authors : Tong, Zhang

• Source: South China Morning Post (Hong Kong). 2023.

Record details

Integration of microbial and chemical synthesis for the efficient production of plitidepsin, a promising anticancer and antiviral agent.

• Source: Cancer Weekly. 2023, pages. 63

Record details

Burden and benefit of antibiotic prophylaxis in cancer chemotherapy.

• Authors : Liss, Blasius; Cornely, Oliver A.

• Source: The Lancet Infectious Diseases. 2016, Vol. 16, Issue 6, pages. 640

Record details

Burden and benefit of antibiotic prophylaxis in cancer chemotherapy.

• Authors : Liss, Blasius; Cornely, Oliver A.

• Source: The Lancet Infectious Diseases. 2016, Vol. 16, Issue 6, pages. 640

Record details

Lunan Pharmaceutical Group Seeks Patent for Epirubicin Hydrochloride Intermediate Compound II.

• Source: Global IP News: Pharmaceutical Patent News. 2022.

Record details

Lunan Pharmaceutical Group Submits Patent Application for Epirubicin Hydrochloride Intermediate Compound III.

• Source: Global IP News: Pharmaceutical Patent News. 2022.

Record details

Activation of the Integrated Stress Response in drug-tolerant melanoma cells confers vulnerability to mitoribosome-targeting antibiotics. (Updated November 18, 2020).

• Source: Immunotherapy Weekly. 2020, pages. 766

Record details

Activation of the Integrated Stress Response in drug-tolerant melanoma cells confers vulnerability to mitoribosome-targeting antibiotics.

• Source: Immunotherapy Weekly. 2020, pages. 772

Record details

Daiichi Sankyo harnesses 'old' R&D to strike cancer drug gold.

• Source: Legal Monitor Worldwide. 2020.

Record details